Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ASCENDIS PHARMA A/S

(ASND)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon? hGH for Patients with Pediatric Growth Hormone Deficiency

11/12/2021 | 07:22am EST

Ascendis Pharma A/S announced that the European Medicine Agency?s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization for Lonapegsomatropin Ascendis Pharma (TransCon hGH). TransCon hGH is a long-acting once-weekly, transiently pegylated somatropin that in the body releases somatropin (also called human growth hormone, or hGH), indicated for growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency, or GHD). The European Commission final decision on the company?s Marketing Authorisation Application (MAA) for TransCon hGH is expected within 67 days after the positive opinion, or by the end of January 2022. The CHMP opinion is based on results submitted in the MAA from the Company?s Phase 3 heiGHt, fliGHt and enliGHten trials, which collectively treated more than 300 pediatric patients diagnosed with GHD. In 2020, Ascendis Pharma received a positive opinion from the Paediatric Committee of the European Medicines Agency for its TransCon hGH Paediatric Investigation Plan, based on the non-clinical safety program as well as data from the three Phase 3 clinical trials included in the MAA. Earlier this year, the U.S. Food & Drug Administration approved TransCon hGH ? marketed in the U.S. under the brand name SKYTROFA? (lonapegsomatropin-tcgd) ? for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb.) and have growth failure due to inadequate secretion of endogenous growth hormone. Ascendis Pharma is also developing TransCon hGH in Japan, and separately in China through VISEN Pharmaceuticals. Pediatric GHD is a serious orphan disease caused when the pituitary gland does not produce enough growth hormone. Children with GHD are not only characterized by short stature; they also may experience metabolic abnormalities, psychosocial challenges, and an overall poor quality of life. For decades, the standard of care for GHD has been a daily subcutaneous injection of hGH to improve growth and overall endocrine health.


ę S&P Capital IQ 2021
All news about ASCENDIS PHARMA A/S
01/13Wedbush Raises Price Target for Ascendis Pharma A/S to $189 From $186 on EU Approval fo..
MT
01/13Ascendis Pharma's Growth Hormone Drug TransCon hGH Gets EU Approval
MT
01/13Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Gr..
AQ
01/13Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Gro..
CI
01/13Wedbush Cuts Ascendis Pharma's PT to $186 From $191 on Skytrofa Contraindication for PW..
MT
01/11European ADRs Nudge Lower in Tuesday Trading
MT
01/10Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic Roadmap at 40th Annual J.P...
AQ
01/06European ADRs Move Higher in Thursday Trading
MT
01/06Cowen Starts Ascendis Pharma at Market Perform With $136 Price Target
MT
01/05European ADRs Move Higher in Wednesday Trading
MT
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Financials
Sales 2021 7,59 M 8,67 M 8,67 M
Net income 2021 -403 M -460 M -460 M
Net cash 2021 677 M 773 M 773 M
P/E ratio 2021 -14,6x
Yield 2021 -
Capitalization 6 121 M 6 986 M 6 986 M
EV / Sales 2021 717x
EV / Sales 2022 88,2x
Nbr of Employees 482
Free-Float 10,5%
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 107,73 €
Average target price 165,96 €
Spread / Average Target 54,1%
EPS Revisions
Managers and Directors
Jan M°ller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprog°e Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-8.60%6 986
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.88%52 722
BIONTECH SE-23.97%47 338